PROCUREMENT

UPDATE Adriana Oxman/Marcos Chaparro Procurement Specialists for the Regional Revolving Funds Department of Procurement and Supply Management

Copenhagen, September 2018

PAHO/WHO

• About PAHO

• Procurement Mechanisms and portfolio

• Top Commodities

OVERVIEW

• Strategies for acquisitions of products and services (Opportunities/Benefits/Challenges)

LONG-TERM AGREEMENTS

• Upcoming tenders

HOW TO DO BUSINESS

The PAHO Revolving Funds

41 countries

and territories

33 countries

and territories Member States using PAHO

Revolving Funds

25 million people are protected

annually with at least one vaccine procured through PAHO

74 LTAs Including HVI/AIDS, TB,

Malaria, Antineoplastic, Antivirals (HCV), Immunosuppressive drugs, Hematologic, Surfactant Diagnostic kits

PAHO Revolving Fund Products portfolio

PAHO Strategic Fund Products portfolio

WHO Essential Medicines

Diagnostics

Vector Control

Other Strategic Products

(e.g. Equipment)

Vaccines Syringes

Cold Chain Equipment

Other biologicals (e.g. blood products)

www.paho.org/revolvingfund www.paho.org/strategicfund

PAHO/WHO HQ Procurement 2006 - 2017

232

282

373 385

579

510

625 597

736

632

740 744

2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

An

nu

al P

O V

alu

e

(in

USD

Mill

ion

)

Year

PAHO/WHO TOP COMMODITIES (USD MILLIONS during 2017)

USD$566.1 M Vaccines, antigens and toxoids

USD$37.7 M Antiretroviral medicines

USD$3.8 M Laboratory & Scientific Equipment

USD$5.2 M CCE, syringes & safety boxes

USD$3.0 M Hematologic medicines

USD$6.0 M Anti-Tuberculosis medicines

USD$11.1 M Disease vector mngt. & control

USD$2.6 M Bio-technology/chemistry, genetic & microbiology and related materials

USD$8.0 M Antiviral medicines (HCV)

USD$1.0 M Amebicides trichomonacides

PAHO/WHO

Strategy for Acquisition of Products

Maximize use of Long-Term Agreements

Regional demand planning and consolidation

(where/when possible)

Key negotiations with sole sources

Exploring new market

opportunities

Joint purchases (where/when

possible)

Continue working in identifying new

sources

PAHO/WHO

• Patent restriction/Joint Venture

• Sole source

• Tier pricing

• New development products

• Demand accuracy

• Eligibility criteria

• Registration in destination

• Shortage

• Language constraints

• Small quantities

CHALLENGES OPPORTUNITIES

• Direct access to 41 countries and territories

• Pool demand/Forecast

• Contract management support

• Expanding access to NCDs (cancer, diabetes, hypertension, hepatitis)

• Piggy-bank with other UN agencies

• One focal point

• Access to new sources for the Region.

• Prompt and guaranteed payment

Long-Term Agreements (LTA) Overview

PAHO/WHO

Human Coagulation Factor September 2018

Antineoplastic medicine October 2018 Immunosuppressive medicine

Q1 2019

Antidiabetic December 2018

Antiretrovirals June 2021

Canine Rabies October 2018

Vaccines 2021-2023 March-June 2020

Vaccines 2021-2022 March-June 2020

Seasonal Influenza Composition Publication/Demand

Syringes/Safety Boxes June 2019

Upcoming Tender Exercises

Cold Chain Equipment Ad-Hoc depending on each Member State’s identified requirements

Micronutrients June 2019

PAHO/WHO

Integrated System:

UNGM (Vendor Registration)

In-Tend (Tendering)

Over 25 UN Agencies use UNGM

as their supplier roster

Search for PAHO procurement:

Doing Business with PAHO

THANK YOU!